Benzyl cinnamate is a balsamic aromatic ester most strongly linked with Peru balsam, tolu balsam, propolis-type materials, and some fragrance applications. The current public evidence base is thinner than for benzyl benzoate or benzyl salicylate: identity and fragrance-safety coverage are clear, while isolated bioactivity evidence is mostly preclinical and mixed in strength. For AromaForge, it is best described as a Peru-balsam-linked marker constituent with limited but real in vitro or screening literature, plus explicit gaps around human and constituent-specific safety data.
Chemical identity and composition
Benzyl cinnamate has formula C16H14O2 and is the ester of benzyl alcohol and cinnamic acid. It is one of the benzenoid-cinnamate esters that help define the resinous profile of Peru balsam style materials, and public synthesis papers also discuss it as a UV-protective and fragrance-use ingredient.
Aroma and practical use
- Use the recorded sweet, balsamic, floral, spicy, powdery descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2021 full-text paper reported benzyl cinnamate production by immobilized lipase and found DPPH radical-scavenging activity with an IC50 of 149.8 mg/mL, which the authors interpreted as low antioxidant activity.
The same paper reported Artemia salina toxicity at much lower concentrations than cinnamic acid, showing that the accessible bioactivity literature is present but not straightforwardly positive.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A PubMed-indexed study on an aqueous extract of Cinnamomi ramulus reported that benzyl cinnamate at 10-100 ug/mL inhibited MH7A cell migration and induced apoptosis.
Because the paper is extract-centered rather than a dedicated single-compound study, this is better treated as provisional constituent-level support rather than a standalone efficacy claim.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Dermatitis literature on propolis identifies benzyl cinnamate as a less frequent sensitizer than the major caffeate allergens.
That supports conservative allergy language without overstating risk relative to better-established propolis sensitizers.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard, Benzyl cinnamate, CAS 103-41-3 (Amendment 49, 2020) - Category 4 (fine fragrance) maximum acceptable concentration in finished product 2.0%; restriction driven by dermal sensitization and systemic toxicity.Accessible safety coverage is driven mainly by fragrance-review literature rather than broad open toxicology dossiers.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Propolis-allergy sources suggest benzyl cinnamate can act as a sensitizer, but usually as a less frequent one than the major caffeate allergens in that matrix.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
Direct human constituent-specific exposure studies were not located in a strong open primary source during this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
free-radical scavenging in a DPPH assay
A full-text synthesis paper measured antioxidant activity for isolated benzyl cinnamate, but the reported IC50 was high and was interpreted by the authors as low antioxidant potency.
This experimental finding does not establish benefit, dose or safety in people using this blend.
cell-migration and apoptosis effects in MH7A fibroblast-like synoviocytes
A PubMed snippet from an extract study reports that benzyl cinnamate at 10-100 ug/mL inhibited migration and induced apoptosis in MH7A cells, but this remains cell-line evidence inside a broader herbal-investigation context.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (3)
- This pass did not locate strong open human clinical literature focused on isolated benzyl cinnamate.
- Most accessible positive bioactivity claims are cell-level, screening-level, or review-level and do not justify strong functional claims.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.